Bristol-Myers Squibb Company
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All BMY news ›Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation. Novo Nordisk dominates the obesity and diabetes markets with exceptional net margins and steady growth. Which of these pharmaceutical…
Bristol-Myers Squibb (BMY) Gets a Sell from Morgan Stanley
Morgan Stanley analyst Terence Flynn assigned a Sell rating to Bristol-Myers Squibb today and set a price target of $40.00. According to TipRanks, Flynn is a 5-star analyst with an average return of 9.1% and a 58.50% success rate. Flynn…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY). Piper Sandler analyst Jason Bednar maintained a Hold rating on…
Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank
In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. According to TipRanks, Chen is a 4-star analyst with an average return of 7.4% and a 53.61% success…
Bristol-Myers Squibb (BMY) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Chris Schott maintained a Buy rating on Bristol-Myers Squibb today and set a price target of $73.00. Schott covers the Healthcare sector, focusing on stocks such as Merck & Company, Bristol-Myers Squibb, and Eli Lilly &…
Bristol Myers Squibb reports 51% lower progression or death risk with Zenbexus regimen
EXCALIBER-RRMM met its second primary endpoint, with median progression-free survival estimated at 42 months versus 20 months. A 51 per cent reduction in progression or death risk for a Zenbexus combination marked its second positive…
Phase 3 Findings Mark Progress in Relapsed or Refractory Multiple Myeloma Treatment – Bristol Myers Squibb
Phase 3 Findings Mark Progress in Relapsed or Refractory Multiple Myeloma Treatment - Bristol Myers Squibb Oncodaily Bristol Myers Squibb shared on LinkedIn: “Today, we announced positive topline results from a Phase 3 trial evaluating our…
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)
If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today. As October gets underway, the S&P 500 index (^GSPC -0.22%) is trading near all-time highs and offering a tiny…
Bristol Myers Squibb ZENBEXUS cuts progression risk 51%
Assets related to this article Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 EXCALIBER-RRMM results showing median progression-free survival of 42 months with ZENBEXUS-based treatment versus 20 months with the comparator…
Bristol Myers Squibb Company $BMY Holdings Lessened by RTD Financial Advisors Inc.
Posted by Danessa Lincoln on Oct 10th, 2026 The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
finance.yahoo.com163
-
tradingview.com156
-
marketscreener.com119
-
theglobeandmail.com67
-
biospace.com57
Measured across the 4Homeopathic news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.